Navigation Links
National Parkinson Foundation Announces Its New President and CEO
Date:3/19/2008

NPF Names New President and CEO

MIAMI, March 19 /PRNewswire-USNewswire/ -- The Board of Directors of the National Parkinson Foundation (NPF) announced today that Joyce A. Oberdorf has been named President and Chief Executive Officer effective April 1. Ms. Oberdorf was most recently Vice President, Policy, Planning and Communications at the Michael J. Fox Foundation for Parkinson Research.

"Ms. Oberdorf is an outstanding choice to help NPF accomplish its strategic goal of remaking the organization to build on our strengths and have an even greater impact on the lives of Parkinson's patients," said Paul Oreffice, Chairman of the Board.

"I look forward to working with Mr. Oreffice, Nat Slewett, Chairman Emeritus and Dr. Bernard Fogel, Dean Emeritus of the Leonard M. Miller School of Medicine at University of Miami, the Board and team at NPF to build on NPF's strengths, which include its proud history, reach, heightened focus on improving patient care in a holistic fashion, and a demonstrated commitment to change," Joyce Oberdorf stated. "Together we will build on the changes already in place to create a new future, focusing on those areas where our mission is most compelling and our impact, the greatest. In addition, we hope to, by example, increase cooperation, coordination and collaboration with our peers and friends in the Parkinson community. In this way, we aim to create a model for improving the clinical microsystem that serves this and future generations of Parkinson's patients in the U.S. and around the world."

Dr. Fogel, who chaired the search committee said that "Ms. Oberdorf is a proven leader and manager. She has demonstrated a unique ability to develop and set forth a strategic vision. She has an excellent understanding of the complex issues surrounding Parkinson's disease, and is highly respected in the community as an individual who truly appreciates the needs and concerns of patients. Ms. Oberdorf wil
'/>"/>

SOURCE National Parkinson Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Statement By Robert McSwain, Acting Director, Indian Health Service, Regarding National Native HIV/AIDS Awareness Day 2008
2. Chindex International, Inc. Announces Three-For-Two Stock Split
3. National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health
4. National Council on Disability Monthly Bulletin for February, 2008
5. Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Investigation
6. Resources Top 400,000 in Hopkins International Information Service
7. National Report on Patient Perspectives of Hospital Care Released Today
8. Country Music Star Troy Gentry Partners With National Non-Profit Patient Advocate Foundation to Spread the Message About Challenges to Healthcare Access for Insured and Uninsured Americans
9. Egyptian foot care center recieves International Diabetes Federation grant
10. Fifth Third Asset Management Supports Disabled Veterans Through National Winter Sports Event
11. Idaho Youth Named National Epilepsy Spokesperson
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 1Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 4Natural born divers and the molecular traces of evolution 9035 1Natural born divers and the molecular traces of evolution 9035 2Reading the brain without poking it 9033 1Reading the brain without poking it 9033 2Reading the brain without poking it 9033 3Reading the brain without poking it 9033 4Reading the brain without poking it 9033 5